Switch strategies in antiretroviral therapy regimens

References

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-60
   PubMed Web of Science ®Google Scholar
• Pulido F, Perez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009;14(2):195-201
   PubMed Web of Science ®Google Scholar
• Campo RE, Da Silva BA, Cotte L, et al. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses 2009;25(3):269-75
   PubMed Web of Science ®Google Scholar
• Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009;51(1):29-36
   PubMed Web of Science ®Google Scholar
• Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007;44(11):1484-92
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, DeJesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010;24(13):2019-27
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, DeJesus E, et al. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials 2012;13(5):233-44
   PubMed Web of Science ®Google Scholar
• Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005;21(10):1683-92
   PubMed Web of Science ®Google Scholar
• Sension M, Andrade Neto JL, Grinsztejn B, et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 2009;51(2):153-62
   PubMed Web of Science ®Google Scholar
• Ghosn J, Carosi G, Moreno S, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010;15(7):993-1002
   PubMed Web of Science ®Google Scholar
• Whol D, Bathti L, Small CB. Simplification to abacavir/lamivudine (ABC/3TC) + atazanavir (ATV)from tenofovir/emtricitabine (TDF/FTC) + ATV/ritonavir maintains viral suppression and improves bone biomarkers (abstract H-556c). 52nd Interscience Conference on ANtimicrobial Agents and Chemotherapy (ICAAC 2012); San Francisco, CA, USA; 2012
   Google Scholar
• Baril J, Conway B, Giguere P, et al. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction. HIV Med 2014;15(5):301-10
   PubMed Web of Science ®Google Scholar
• Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Med 2014;15(6):330-8
   PubMed Web of Science ®Google Scholar
• Saumoy M, Ordonez-Llanos J, Martinez E, et al. LDL Particles and Lipoprotein-Phospholipase A2 in Naive HIV+ Patients Randomized To DRV/r vs ATV/r (abstract 745). 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); Boston, MA, USA; 2014
   Google Scholar
• Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349(11):1036-46
   PubMed Web of Science ®Google Scholar
• Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010;4:115-25
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010;24(18):2835-40
   PubMed Web of Science ®Google Scholar
• DeJesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51(2):163-74
   PubMed Web of Science ®Google Scholar
• Fisher M, Palella F, Tebas P. SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48 (abstract P285). 11th International Congress on Drug Therapy in HIV infection; Glasgow, UK; 2012
   Google Scholar
• Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014;28(3):335-44
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010;24(11):1697-707
   PubMed Web of Science ®Google Scholar
• Saumoy M, Sanchez-Quesada JL, Martinez E, et al. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: spiral substudy. Atherosclerosis 2012;225(1):200-7
   PubMed Web of Science ®Google Scholar
• Martinez E, D’Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012;26(18):2315-26
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2014. Available from: http://aidsinfonih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
   Google Scholar
• Arribas J, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014;14:581-9
   PubMed Web of Science ®Google Scholar
• German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012;61(1):32-40
   PubMed Web of Science ®Google Scholar
• Martinez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009;51(3):290-7
   PubMed Web of Science ®Google Scholar
• Saumoy M, Ordonez-Llanos J, Martinez E, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther 2011;16(4):459-68
   PubMed Web of Science ®Google Scholar
• Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009;49(10):1591-601
   PubMed Web of Science ®Google Scholar
• Campo R, DeJesus E, Bredeek UF, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013;56(11):1637-45
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Massari V, Rey D, et al. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis 2007;45(2):263-6
   PubMed Web of Science ®Google Scholar
• Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. J Acquir Immune Defic Syndr 2005;38(5):560-5
   PubMed Web of Science ®Google Scholar
• Waters L, Fisher M, Winston A, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011;25(1):65-71
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011;25(1):57-63
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011;25(12):1481-7
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Ruane P. Switch from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir DF: efficacy and pharmacokinetics (abstract H-658). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013); Denver, CO, USA; 2013
   Google Scholar
• Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis 2014;14:590-9
   PubMed Web of Science ®Google Scholar
• Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998;339(18):1261-8
   PubMed Web of Science ®Google Scholar
• Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008;22(2):F1-9
   PubMed Web of Science ®Google Scholar
• Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009;51(2):147-52
   PubMed Web of Science ®Google Scholar
• Bierman WF, van Agtmael MA, Nijhuis M, et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009;23(3):279-91
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009;199(6):866-71
   PubMed Web of Science ®Google Scholar
• Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007;44(4):417-22
   PubMed Web of Science ®Google Scholar
• Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS 2009;23(1):83-7
   PubMed Web of Science ®Google Scholar
• Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24(2):223-30
   PubMed Web of Science ®Google Scholar
• Clumeck N, Rieger A, Banhegyi D, et al. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother 2011;66(8):1878-85
   PubMed Web of Science ®Google Scholar
• Arribas JR, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med 2012;13(7):398-405
   PubMed Web of Science ®Google Scholar
• Katlama C, Valantin MA, Garte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010;24(15):2365-74
   PubMed Web of Science ®Google Scholar
• Valantin MA, Lambert-Niclot S, Flandre P, et al. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study. J Antimicrob Chemother 2012;67(3):691-5
   PubMed Web of Science ®Google Scholar
• Reynes J, Lawal A, Pulido F, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results. HIV Clin Trials 2011;12(5):255-67
   PubMed Web of Science ®Google Scholar
• Kozal MJ, Lupo S, DeJesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clin Trials 2012;13(3):119-30
   PubMed Web of Science ®Google Scholar
• Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011;25(17):2113-22
   PubMed Web of Science ®Google Scholar
• Cahn P. Dual therapy with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) is non-inferior to standard triple drug therapy in naive HIV-1 infected subjects: 48-week results of the GARDEL study (abstract LBPS7/6). 14th European AIDS Conference (EACS 2013); Brussels, Belgium; 2013
   Google Scholar
• Study to evaluate the activity and tolerability of lopinavir/ritonavir and lamivudine bitherapy in HIV patients with viral suppression (OLE). 2014. Available from: http://clinicaltrialsgov/show/NCT01471821
   Google Scholar
• Perez-Molina JA, Rivero A, Pasquau R, et al. GESIDA 7011 study group. Safety and efficacy of switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. triple therapy (atazanavir/ritonavir+two nucleos(t)ides) in patients on virologically stable antiretroviral therapy: 24-week interim analysis from a randomized clinical trial (SALT study). 14th European AIDS Conference (EACS 2013); Brussels, Belgium, 2013. Poster PE7/1 2014)
   Google Scholar
• Katlama C, Assoumou L, Valantine MA, et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother 2014;69(6):1648-52
   PubMed Web of Science ®Google Scholar
• Calin R, Paris L, Simon A, et al. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy. Antivir Ther 2012;17(8):1601-4
   PubMed Web of Science ®Google Scholar
• Monteiro P, Perez I, Laguno M, et al. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother 2014;69(3):742-8
   PubMed Web of Science ®Google Scholar
• Lambert-Niclot S, Flandre P, Valantin MA, et al. Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy. J Infect Dis 2011;204(8):1211-16
   PubMed Web of Science ®Google Scholar
• Rockstroh J, Bhagani S, Bruno R. European AIDS Clinical Society (EACS) guidelines. Version 6.1.2012. 2012. Available from: www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf
   Google Scholar
• Llibre JM, Cardona G, Santos JR, et al. Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain. ClinicoEcon Outcomes Res 2013;5:215-21
   PubMedGoogle Scholar
• A trial comparing GSK1349572 50mg plus abacavir/lamivudine once daily to atripla (also called the SINGLE Trial). Available from: http://clinicaltrials.gov/show/NCT01263015
   Google Scholar
• Pharmacokinetics, safety, and efficacy of cobicistat-boosted atazanavir or cobicistat-boosted darunavir in HIV-1 infected, treatment-experienced, virologically suppressed pediatric subjects. Available from: http://clinicaltrials.gov/show/NCT02016924
   Google Scholar
• Study to evaluate the safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in HIV-1 positive, antiretroviral treatment-naïve adults. Available from: http://clinicaltrials.gov/show/NCT01780506
   Google Scholar
• A phase IIb study evaluating a long-acting intramuscular regimen of GSK1265744 plus TMC278 for the maintenance of virologic suppression following an induction of virologic suppression on an oral regimen of GSK1265744 plus abacavir/lamivudine in HIV-1 infected, antiretroviral therapy-naive adult subjects. Available from: http://clinicaltrials.gov/show/NCT02120352
   Google Scholar